Top-Rated StocksTop-RatedNASDAQ:ACLX Arcellx (ACLX) Stock Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free ACLX Stock Alerts $52.79 +1.07 (+2.07%) (As of 05/16/2024 ET) Add Compare Share Share Today's Range$51.00▼$53.1150-Day Range$49.74▼$73.4952-Week Range$30.74▼$75.10Volume538,361 shsAverage Volume455,828 shsMarket Capitalization$2.82 billionP/E RatioN/ADividend YieldN/APrice Target$78.73 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Arcellx alerts: Email Address Arcellx MarketRank™ Stock AnalysisAnalyst RatingBuy3.08 Rating ScoreUpside/Downside49.1% Upside$78.73 Price TargetShort InterestBearish8.89% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.56Based on 27 Articles This WeekInsider TradingSelling Shares$42.97 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.68) to ($1.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.99 out of 5 starsMedical Sector393rd out of 929 stocksBiological Products, Except Diagnostic Industry53rd out of 155 stocks 4.5 Analyst's Opinion Consensus RatingArcellx has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 12 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArcellx has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arcellx's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.89% of the float of Arcellx has been sold short.Short Interest Ratio / Days to CoverArcellx has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Arcellx has recently decreased by 3.97%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldArcellx does not currently pay a dividend.Dividend GrowthArcellx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACLX. Previous Next 2.5 News and Social Media Coverage News SentimentArcellx has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 27 news articles for Arcellx this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for ACLX on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.MarketBeat Follows3 people have added Arcellx to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcellx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,965,930.00 in company stock.Percentage Held by InsidersOnly 6.24% of the stock of Arcellx is held by insiders.Percentage Held by Institutions96.03% of the stock of Arcellx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcellx's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arcellx are expected to decrease in the coming year, from ($1.68) to ($1.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcellx is -51.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcellx is -51.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcellx has a P/B Ratio of 5.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arcellx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaAmericans Now Need $1.46M to Retire…Americans now say they need $1.46M in order to “retire comfortably.” For many, retiring in your 60s may be out of the picture altogether… But luckily for you – a limited window in today’s crypto market could help you retire quickly in wealth AND comfort!Click here to access the free Crypto Retirement Blueprint now. About Arcellx Stock (NASDAQ:ACLX)Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Read More ACLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACLX Stock News HeadlinesMay 4, 2024 | insidertrades.comArcellx, Inc. (NASDAQ:ACLX) Insider Christopher Heery Sells 18,168 SharesApril 19, 2024 | insidertrades.comArcellx, Inc. (NASDAQ:ACLX) Director Olivia C. Ware Sells 9,402 SharesMay 16 at 6:38 AM | americanbankingnews.comArcellx (NASDAQ:ACLX) Upgraded to "Strong-Buy" at Evercore ISIMay 16 at 1:38 AM | americanbankingnews.comArcellx (NASDAQ:ACLX) Trading 6.6% Higher Following Analyst UpgradeMay 15 at 6:18 AM | americanbankingnews.comEvercore ISI Initiates Coverage on Arcellx (NASDAQ:ACLX)May 15 at 4:54 AM | americanbankingnews.comArcellx (NASDAQ:ACLX) PT Lowered to $80.00May 14 at 11:13 PM | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Arcellx Inc (ACLX)May 14 at 6:13 PM | msn.comEvercore ISI Group Initiates Coverage of Arcellx (ACLX) with Outperform RecommendationMay 14 at 9:43 AM | markets.businessinsider.comBuy Rating for Arcellx Inc. on Promising CAR-T Cell Therapy Trials and Strategic Market PositioningMay 14 at 9:43 AM | markets.businessinsider.comAnalyst Expectations For Arcellx's FutureMay 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arcellx Inc. Amidst Promising Trial Progress and Strategic PartnershipsMay 12, 2024 | finance.yahoo.comArcellx First Quarter 2024 Earnings: Beats ExpectationsMay 12, 2024 | americanbankingnews.comArcellx (NASDAQ:ACLX) Trading Down 6.1%May 11, 2024 | markets.businessinsider.comBuy Rating Justified for Arcellx Inc. Amidst Progress in Anito-cel’s Clinical Development and Regulatory MilestonesMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arcellx Inc on Robust iMMagine-3 Study Prospects and Efficient ManufacturingMay 10, 2024 | markets.businessinsider.comBarclays Reaffirms Their Buy Rating on Arcellx Inc (ACLX)May 10, 2024 | finance.yahoo.comArcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue SurgeMay 10, 2024 | markets.businessinsider.comBuy Rating for Arcellx Inc: Strategic Positioning and Promising Clinical Trials Fuel Positive OutlookMay 10, 2024 | investorplace.comACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | msn.comGilead's Kite, Arcellx share phase 3 trial design for CAR-T multiple myeloma assetMay 9, 2024 | businesswire.comKite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma ProgramMay 9, 2024 | businesswire.comArcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma ProgramMay 9, 2024 | businesswire.comArcellx Provides First Quarter 2024 Financial ResultsMay 9, 2024 | investorplace.comBiotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing MedicineMay 8, 2024 | americanbankingnews.comArcellx (NASDAQ:ACLX) Given "Buy" Rating at Needham & Company LLCSee More Headlines Receive ACLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/16/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ACLX CUSIPN/A CIK1786205 Webarcellx.com Phone240-327-0603FaxN/AEmployees130Year FoundedN/APrice Target and Rating Average Stock Price Target$78.73 High Stock Price Target$87.00 Low Stock Price Target$52.00 Potential Upside/Downside+49.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,690,000.00 Net Margins-38.39% Pretax Margin-38.13% Return on Equity-13.11% Return on Assets-7.11% Debt Debt-to-Equity RatioN/A Current Ratio5.46 Quick Ratio5.46 Sales & Book Value Annual Sales$110.32 million Price / Sales25.60 Cash FlowN/A Price / Cash FlowN/A Book Value$9.28 per share Price / Book5.69Miscellaneous Outstanding Shares53,500,000Free Float50,164,000Market Cap$2.82 billion OptionableOptionable Beta0.24 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Rami Elghandour (Age 45)Chairman of the Board, CEO & President Comp: $1.02MMs. Michelle Lim Gilson (Age 31)Chief Financial Officer Comp: $832.8kDr. Christopher R. Heery M.D. (Age 44)Chief Medical Officer Comp: $688.55kMr. Narinderjeet Singh M.S. (Age 52)Chief Technical Officer Mr. David Tice Ph.D. (Age 53)Chief Scientific Officer Ms. Myesha LacyChief Investor & Communications OfficerMs. Maryam Abdul-Kareem J.D.M.S., General CounselMs. Kate AikenChief People OfficerMr. Neeraj P. Teotia (Age 49)Chief Commercial Officer Comp: $461.95kMs. Aileen FernandesChief Business OfficerMore ExecutivesKey CompetitorsTwist BioscienceNASDAQ:TWSTImmunocoreNASDAQ:IMCRDenali TherapeuticsNASDAQ:DNLIIovance BiotherapeuticsNASDAQ:IOVAVericelNASDAQ:VCELView All CompetitorsInsiders & InstitutionsJanus Henderson Group PLCSold 15,901 shares on 5/16/2024Ownership: 2.845%California State Teachers Retirement SystemSold 2,610 shares on 5/16/2024Ownership: 0.055%Price T Rowe Associates Inc. MDBought 84,373 shares on 5/15/2024Ownership: 2.513%Affinity Asset Advisors LLCSold 40,000 shares on 5/15/2024Ownership: 0.561%Lazard Asset Management LLCSold 308 shares on 5/15/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions ACLX Stock Analysis - Frequently Asked Questions Should I buy or sell Arcellx stock right now? 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcellx in the last twelve months. There are currently 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACLX shares. View ACLX analyst ratings or view top-rated stocks. What is Arcellx's stock price target for 2024? 13 Wall Street research analysts have issued twelve-month target prices for Arcellx's shares. Their ACLX share price targets range from $52.00 to $87.00. On average, they expect the company's share price to reach $78.73 in the next twelve months. This suggests a possible upside of 49.1% from the stock's current price. View analysts price targets for ACLX or view top-rated stocks among Wall Street analysts. How have ACLX shares performed in 2024? Arcellx's stock was trading at $55.50 at the beginning of the year. Since then, ACLX shares have decreased by 4.9% and is now trading at $52.79. View the best growth stocks for 2024 here. When is Arcellx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our ACLX earnings forecast. How were Arcellx's earnings last quarter? Arcellx, Inc. (NASDAQ:ACLX) released its quarterly earnings data on Thursday, May, 9th. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.51) by $0.37. The firm had revenue of $39.26 million for the quarter, compared to the consensus estimate of $20.67 million. Arcellx had a negative net margin of 38.39% and a negative trailing twelve-month return on equity of 13.11%. The firm's quarterly revenue was up 119.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.58) EPS. What ETFs hold Arcellx's stock? ETFs with the largest weight of Arcellx (NASDAQ:ACLX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), ALPS Medical Breakthroughs ETF (SBIO), Tema Oncology ETF (CANC), Harbor Corporate Culture Small Cap ETF (HAPS) and Principal Healthcare Innovators ETF (BTEC).First Trust Nasdaq Pharmaceuticals ETF (FTXH). When did Arcellx IPO? Arcellx (ACLX) raised $132 million in an initial public offering (IPO) on Friday, February 4th 2022. The company issued 8,250,000 shares at a price of $15.00-$17.00 per share. Who are Arcellx's major shareholders? Arcellx's stock is owned by many different retail and institutional investors. Top institutional investors include SR One Capital Management LP (4.39%), Vanguard Group Inc. (4.18%), Janus Henderson Group PLC (2.85%), Price T Rowe Associates Inc. MD (2.51%), Lord Abbett & CO. LLC (2.25%) and Affinity Asset Advisors LLC (0.56%). Insiders that own company stock include Christopher Heery, Enterprise Associates 15 New, Jill Carroll, Michelle Gilson, Olivia C Ware, Rami Elghandour, Scott D Sandell and Sr One Capital Management, Llc. View institutional ownership trends. How do I buy shares of Arcellx? Shares of ACLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACLX) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsObama’s Forever Term [exposed]Porter & CompanyGold Set to EXPLODE!Gold Safe ExchangeThe 1,000X Crypto PlaybookTrue Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressWhy Is Gold On a MASSIVE rally? Huge AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcellx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
